



OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

March 4, 2025

BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure, will present and be available for one-on-one investor meetings at the following investor conferences:

- A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A live audio webcast will be available through this [link](#) and the Investors section of OnKure's website at www.onkure.com. Following the event, a replay will be available on the OnKure website for at least 90 days.
- A fireside chat at the Stifel Targeted Oncology Forum, which will be held virtually April 8-9, 2025. Additional information will be available on the OnKure website.

About OnKure Therapeutics

OnKure Therapeutics, Inc. (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure- and computational chemistry-driven drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3K α^{H1047R} inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3K α and has multiple programs designed to enable best-in-class targeting of this key oncogene.

For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.

Contact:

Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com